WCA
PCRX icon

Westover Capital Advisors’s Pacira BioSciences PCRX Stock Holding History

Westover Capital Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,810
Closed -$828K – 182
2021
Q1 		$828K Buy
+11,810
New +$844K 0.28% 78

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Westover Capital Advisors's PCRX Position: Q2 2021 in Review

Westover Capital Advisors sold out of Pacira BioSciences (PCRX) in Q2 2021, closing a stake of 11,810 shares — an estimated $828K sold.

Westover Capital Advisors first reported a position in PCRX in Q1 2021 and held it in 1 quarter. The position peaked at $828K in Q1 2021. 262 funds tracked by Wall St. Rank hold PCRX as of Q2 2021.

  • Westover Capital Advisors reported no remaining Pacira BioSciences position as of Q2 2021 after selling out during the quarter.
  • Westover Capital Advisors sold 11,810 Pacira BioSciences shares in Q2 2021, an estimated $828K.
  • Westover Capital Advisors first reported a position in Pacira BioSciences in Q1 2021 and held it in 1 quarter.
  • Westover Capital Advisors's Pacira BioSciences position peaked at $828K in Q1 2021.
  • 262 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2021.

Based on Westover Capital Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.